



UNIVERSITÀ DI PISA



## MARCO FALCONE

### Curriculum Vitae

#### Parte I – Informazioni generali

Nome	MARCO FALCONE
Data di nascita	26/01/1978
Luogo di nascita	COSENZA
Cittadinanza	ITALIANA
Indirizzo di residenza	VIA DELLA GIULIANA 37, 00195 ROMA
E-mail	marco.falcone@unipi.it
Lingue straniere	INGLESE (OTTIMO), SPAGNOLO (OTTIMO)

#### Parte II – Formazione

Tipo	Anno	Istituzione	Note
Laurea	2002	SAPIENZA UNIVERSITA' DI ROMA	Medicina e Chirurgia, voto 110/110 e lode
Specializzazione	2007	SAPIENZA UNIVERSITA' DI ROMA	Medicina Interna, voto 70/70 e lode
Formazione post-laurea	2006	UNIVERSITAT AUTONOMA DE BARCELONA	Fellowship semestrale presso il Centro Trapianti dell'ospedale Vall d'Hebron di Barcellona sulle infezioni nel trapianto d'organo solido

#### Parte III – Carriera accademica

Inizio	Fine	Istituzione	Posizione
2008	2011	Facoltà di Medicina e Chirurgia, SAPIENZA Università di Roma	Assegnista di ricerca, settore scientifico-disciplinare MED/09 Medicina Interna
2011	2013	Dipartimento di Sanità Pubblica e Malattie Infettive, SAPIENZA Università di Roma	Assegnista di ricerca, settore scientifico-disciplinare MED/17 Malattie Infettive
2013	2018	Dipartimento di Sanità Pubblica e Malattie Infettive, Facoltà di Farmacia e Medicina, SAPIENZA Università di Roma	Ricercatore di tipo A (RTD-A) settore scientifico disciplinare MED/17 Malattie Infettive
2015	-->	Scuola degli Studi Avanzati Sapienza (SSAS).	Fellow
Giugno 2018	Ottobre 2020	Dipartimento di Medicina Clinica e Sperimentale, Università di PISA.	Ricercatore di tipo B (RTD-B) settore scientifico disciplinare MED/17 Malattie Infettive

Novembre 2020	Maggio 2022	Dipartimento di Medicina Clinica e Sperimentale, Università di PISA.	Professore Associato, settore scientifico disciplinare MED/17 Malattie Infettive
Giugno 2022	----->	Dipartimento di Medicina Clinica e Sperimentale, Università di PISA.	Professore Ordinario di Malattie Infettive, settore scientifico disciplinare MED/17

#### Parte IV - Attività didattica Universitaria

Inizio	Fine	Insegnamento	Istituzione
2015	2018	Patologia Integrata V. Insegnamento di Malattie Infettive-MED/17 (1 CFU)	Corso B della Facoltà di Medicina e Chirurgia, "Sapienza" Università di Roma
2016	2018	Medicina Globale (4 CFU). <b>Coordinatore del corso</b>	Area Scienze della Vita, Scuola degli Studi Avanzati Sapienza (SSAS),
2018	---->	Patologia Sistemica II. Insegnamento di Malattie Infettive-MED17 (3 CFU) <b>Coordinatore del Corso</b>	Corso di Studi in Medicina e Chirurgia, Università di Pisa
2020	---->	Modulo dell'insegnamento SCIENZE MEDICHE I – Malattie Infettive (1 CFU)	Corso di Laurea in Odontoiatria e Protesi Dentaria, Università di Pisa.

#### Parte V - Riconoscimenti e affiliazione a Società Scientifiche

Anno	Titolo
2009	Premiato dalla SIMI/Fondazione Aventis quale miglior giovane ricercatore in Italia anno 2009.
2014	Premio Emanuel Wolinsky Award della Infectious Diseases Society of America (IDSA) in qualità di co-autore del miglior articolo scientifico pubblicato su <i>Clinical Infectious Diseases</i> nell'anno 2013 (Clin Infect Dis 2013;56:1261-8.)
2019	Eletto nel Consiglio Direttivo della <b>Società Italiana di Malattie Infettive e Tropicali (SIMIT)</b>
2019	Eletto nel Consiglio Direttivo del Gruppo Italiano Stewardship Antimicrobica ( <b>GISA</b> )
2019	Nominato Coordinatore dell'area tematica di ricerca in Malattie Infettive dalla Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti ( <b>FADOI</b> )
2020	Nominato <b>Presidente</b> del Gruppo Europeo di Studio per le Infezioni nell'Anziano (ESCMID Study Group for Infections in the Elderly – <b>ESGIE</b> ).
2021	Eletto <b>Segretario</b> della Società Italiana di Malattie Infettive e Tropicali ( <b>SIMIT</b> )

#### Parte VI – Sintesi dell'attività di Ricerca

Parole chiave	Descrizione
- Infezioni nosocomiali - Antibiotico-resistenza - Batteriemia/sepsi - Covid-19 - Antimicrobial Stewardship	Il Prof. Marco Falcone, sin da studente, ha iniziato una attività di ricerca focalizzata sulle infezioni da germi antibiotico-resistenti e sulle complicanze infettive nel malato immunodepresso. L'obiettivo della sua attività è quello di traslare nella pratica clinica le conoscenze molecolari e farmacologiche che derivano dallo studio del paziente con infezione grave, ai fini di una ottimizzazione della terapia antinfettiva. E' Segretario della Società Italiana di Malattie Infettive e Tropicali (SIMIT) e Chair del gruppo europeo delle infezioni nell'anziano (ESGIE) della Società Europea di Malattie Infettive (ESCMID). Nel corso del solo anno 2022 ha collezionato 2.107 citazioni su Scopus. E' il professore Ordinario più giovane d'Italia nel settore Malattie Infettive MED-17.

### Parte VII– Sintesi della produzione scientifica e parametri bibliometrici.

Prodotto	Numero	Database	Inizio	Fine
Articoli internazionali	230	PUBMED	2002	2022
Totale delle citazioni	<b>14.983</b> (Google Scholar, 28 Novembre 2023, <a href="https://scholar.google.com/citations?user=j39SxYwAAAAJ&amp;hl=en&amp;oi=ao">https://scholar.google.com/citations?user=j39SxYwAAAAJ&amp;hl=en&amp;oi=ao</a> ) <b>10.083</b> (Scopus, 28 Novembre 2023, <a href="https://www.scopus.com/authid/detail.uri?authorId=7006839337">https://www.scopus.com/authid/detail.uri?authorId=7006839337</a> )			
Hirsch (H) index	<b>63</b> (Google Scholar, 28 Novembre 2023, <a href="https://scholar.google.com/citations?user=j39SxYwAAAAJ&amp;hl=en&amp;oi=ao">https://scholar.google.com/citations?user=j39SxYwAAAAJ&amp;hl=en&amp;oi=ao</a> ) <b>51</b> (Scopus, 28 Novembre 2023, <a href="https://www.scopus.com/authid/detail.uri?authorId=7006839337">https://www.scopus.com/authid/detail.uri?authorId=7006839337</a> )			
Impact factor totale	<b>&gt; 1.700 punti</b>			

### Parte VIII – Esperienze professionali ed attività assistenziale

2009	2011	Policlinico Umberto I, Roma	Dirigente Medico Dipartimento Malattie Infettive, UOC M. Infettive (Direttore V. Vullo)
2011	2014	Policlinico Umberto I, Roma	Dirigente Medico, Dipartimento di Emergenza e Accettazione (DEA), Direttore C. Modini
Giugno 2018	---→	Azienda Ospedaliera Universitaria Pisana, Cisanello. Pisa	Dirigente Medico, Clinica delle Malattie Infettive (Direttore F. Menichetti)
Giugno 2022	---→	Azienda Ospedaliera Universitaria Pisana, Cisanello. Pisa	Direttore dell'Unità Operativa a direzione universitaria "Clinica e Terapia delle infezioni altamente diffuse e da microrganismi resistenti agli antimicrobici". L'Unità si occupa della cura e della diagnosi delle infezioni ospedaliere e da virus diffusivi quali Covid-19, influenza, malattie contagiose

## LISTA DELLE PUBBLICAZIONI INTERNAZIONALI INDICIZZATE DEL PROF. MARCO FALCONE

1. Pavoni GL, **Falcone M**, Baiocchi P et al. Conservative medical therapy of infections following osteosynthesis: a retrospective analysis of a six-year experience. *J Chemother* 2002; 14: 378-383.
2. **Falcone M**, Carfagna P, Cassone et al. *Staphylococcus aureus* septicemia in hospitalized non-neutropenic adult patients: a retrospective clinical and microbiological analysis. *Ann Ital Med Intern* 2002; 17: 166-172.
3. Venditti M, **Falcone M**, Micozzi A et al. *Staphylococcus aureus* bacteremia in patients with hematologic malignancies: a retrospective case-control study. *Haematologica* 2003 88: 923-930.
4. Pavoni GL, Giannella M, **Falcone M**, et al. Conservative medical therapy of prosthetic joints infections: a retrospective analysis of an eight-year experience. *Clin Microbiol Infect* 2004; 10: 831-7.
5. **Falcone M**, Micozzi A, Pompeo ME et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of *S. haemolyticus*, *S. epidermidis* and *S. aureus*. *J Chemother* 2004; 16: 540-8.
6. **Falcone M**, Pompeo ME, Pavoni GL, et al. Successful conservative treatment of descending necrotizing mediastinitis with fistula formation in the hypopharynx. *Infect Dis Clin Pract* 2005; 13: 1-3.
7. **Falcone M**, Serra P. Massive pulmonary embolism in woman with leiomyomatous uterus determining pelvic deep vein thrombosis. *Ann Ital Med Intern* 2005; 20: 104-7.
8. Pistella E, **Falcone M**, Baiocchi P, et al. *In vitro* activity of fosfomicin in combination with vancomycin or teicoplanin against *Staphylococcus aureus* isolated from device-associated infections unresponsive to glycopeptide therapy. *Infez Med* 2005; 13: 97-102.
9. **Falcone M**, Giannella M, Raponi G, Mancini C, Venditti M. Teicoplanin use and emergence of *Staphylococcus haemolyticus*: is there a link? *Clin Microbiol Infect* 2006; 12: 96-7.
10. **Falcone M**, Campanile F, Giannella M, et al. *Staphylococcus haemolyticus* endocarditis: clinical and microbiological analysis of four cases. *Diagn Microbiol Infect Dis* 2007; 57: 325-31.
11. **Falcone M**, Pompeo ME, Fabi F, Venditti M. Linezolid therapy for the treatment of nocardial infection: report of a case and review of the literature. *Infez Med* 2008, 2: 94-98.
12. Perilli M, Mezzatesta ML, **Falcone M**, et al. Class I integron-borne blaVIM-1 carbapenemase in a strain of *Enterobacter cloacae* responsible for a fatal pneumonia. *Microb Drug Resist* 2008, 14: 45-47.
13. **Falcone M**, Serra P, Licata G, Venditti M, for the Italian Society of Internal Medicine (SIMI). Healthcare-associated pneumonia: a new clinical entity. *Arch Intern Med* (actually JAMA Internal Med) 2008; 168: 109-110.
14. Campanile F, Bongiorno D, Borbone S, **Falcone M**, Giannella M, Venditti M, Stefani S. *In vitro* activity of daptomycin against methicillin- and multi-resistant *Staphylococcus haemolyticus* invasive isolates carrying different mec complexes. *Diagn Microbiol Infect Dis* 2008; 61: 227-31.
15. D'Ettore G, Ceccarelli G, Zaffiri L, **Falcone M**, Mastroianni CM, Venditti M, Vullo V et al. Infectious aortitis and spondylodiscitis in patient with endovascular stent. *Minerva Med* 2009; 100:167-70.
16. Campanile F, Carretto E, Barbarici D, Grigis A, **Falcone M**, et al. The clonal nature of multidrug resistant (MDR) *Corynebacterium striatum* strains responsible for various infections in Italy. *Emerg Infect Dis* 2009, 15:75-78.
17. Venditti M, **Falcone M**, Corrao S, Licata G, Serra P, and the Study Group of the Italian Society of Internal Medicine. Comparison of the outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. *Ann Intern Med* 2009; 150: 19-26.
18. **Falcone M**, Barzaghi N, Carosi G, et al; Italian Study on Endocarditis. *Candida* infective endocarditis: report of 15 cases from a prospective multicenter study. *Medicine (Baltimore)*. 2009; 88:160-8.
19. **Falcone M**, Serra P, Venditti M. Serious infections due to methicillin-resistant *Staphylococcus aureus*: an evolving challenge for physicians. *Eur J Intern Med* 2009; 20:343-7.
20. **Falcone M**, Mezzatesta ML, Perilli M, et al. VIM-1 metallo- $\beta$ -lactamase producing *Enterobacter cloacae* infections and their correlation with clinical outcome. *J Clin Microbiol* 2009,47: 3514-19.
21. **Falcone M**, Perilli MG, Mezzatesta ML, et al. Prolonged bacteremia caused by VIM-1 metallo- $\beta$ -lactamase-producing *Proteus mirabilis*: first report from Italy. *Clin Microbiol Infect* 2010;16:179-81.
22. Russo A, Angeletti S, Lorino G, Venditti C, **Falcone M**, et al. A case of *Lactobacillus casei* bacteraemia associated with aortic dissection: is there a link? *New Microbiol* 2010; 33: 175-8.
23. d'Ettore G, Marchetti F, Ceccarelli G, Gizzi F, Tierno F, **Falcone M**, et al. Surgical debridement with muscle flap transposition and systemic teicoplanin therapy for infected hip arthroplasty. *Hip Int* 2010; 20:255-7.
24. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, **Falcone M**, et al. Cirrhotic patients are at risk for healthcare-associated bacterial infections. *Clin Gastroenterol Hepatol* 2010; 8:979-85.
25. **Falcone M**, Accarpio F, Venditti M, et al. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. *J Antimicrob Chemother* 2010;65:2266-7.
26. **Falcone M**, Russo A, De Rosa FG, et al. Clinical experience of anidulafungin for the treatment of patients with documented candidemia. *J Chemother* 2010; 22:397-401.
27. **Falcone M**, Massetti AP, Russo A et al. Invasive aspergillosis in patients with liver disease. *Med Mycol* 2011; 49:406-13.
28. **Falcone M**, Venditti M, Corrao S, Serra P, for the Italian Society of Internal Medicine (SIMI) Study Group. Role of multidrug-resistant pathogens in health-care-associated pneumonia. *Lancet Infect Dis* 2011; 11: 11-12.
29. **Falcone M**, Corrao S, Venditti M, Serra P, Licata G. Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. *Intern Emerg Med*. 2011; 6: 431-436.
30. Orsi GB, Garcia-Fernandez A, Giordano A, Venditti C, Bencardino A, Gianfreda R, **Falcone M** et al. Risk factors for and clinical significance of ertapenem-resistant *Klebsiella pneumoniae* in hospitalised patients. *J Hosp Infect* 2011; 78:54-8.
31. **Falcone M**, Kollef MH. Antibiotic therapy of healthcare-associated pneumonia. *Minerva Pneumol* 2011; 50:83-92.
32. Orsi GB, **Falcone M**, Venditti M. Surveillance and management of multidrug-resistant microorganisms. *Expert Rev Anti Infect Ther* 2011; 9: 653-79.

33. **Falcone M**, Shindo Y, Venditti M, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community acquired pneumonia. *Int J Infect Dis* 2011; 15: e545-50.
34. Russo A, **Falcone M**, Vena A, et al. Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. *J Chemother* 2011;23: 290-4.
35. Campanile F, Bongiorno D, **Falcone M**, et al. Changing Italian nosocomial-community trends and heteroresistance in *Staphylococcus aureus* from bacteremia and endocarditis. *Eur J Clin Microbiol Infect Dis* 2012; 31:739-45.
36. **Falcone M**, Russo A, Pompeo ME, et al. A retrospective case control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. *Int J Antimicrob Agents* 2012;39: 64-8.
37. Caccese R, Carfagna P, Pistilli N, Massetti AP, **Falcone M**, and Venditti M. *Candida* thrombophlebitis of central veins: case report and review. *Med Mycol* 2012; 50:299-304.
38. **Falcone M**, Venditti M. Community-acquired MRSA: a potentially dangerous but invisible enemy. *Minerva Anestesiol.* 2012; 78(8):865-7.
39. **Falcone M**, Blasi F, Menichetti F, Pea F, Violi F. Pneumonia in older frail patients: an up to date. *Intern Emerg Med* 2012; 7:415-24.
40. **Falcone M**, Corrao S, Licata G, Serra P, Venditti M, on behalf of the Italian Society of Internal Medicine (SIMI). Clinical impact of broad spectrum empirical antibiotic therapy in patients with Healthcare-Associated Pneumonia: a multicenter interventional study. *Intern Emerg Med* 2012; 7: 523-31.
41. Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, Barzaghi N, **Falcone M**, et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. *Infection.* 2012; 40:527-35.
42. Giuliano S, Caccese R, Carfagna P, Vena A, **Falcone M**, Venditti M. Endocarditis caused by nutritionally variant streptococci: a case report and literature review. *Infez Med.* 2012; 20:67-74.
43. **Falcone M**, Russo A, Cassetta M, et al. Daptomycin serum levels in critical patients undergoing continuous renal replacement. *J Chemother* 2012; 24:253-6.
44. Orsi GB, Bencardino A, Vena A, Carattoli A, Venditti C, **Falcone M**, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant *Klebsiella pneumoniae* isolation: results of a double case-control study. *Infection.* 2013; 41:61-7.
45. Campanile F, Mongelli G, Bongiorno D, Adembri C, Ballardini M, **Falcone M**, et al. Worrisome trend in new multiple mechanisms of linezolid-resistant staphylococcal clones diffused in Italy. *J Clin Microbiol* 2013;51:1256-9
46. Ceccarelli G, Giuliano S, **Falcone M** and Venditti M. Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidaemia in neurosurgical patient with early tracheostomy intubation. *Crit Care* 2013; 17:414
47. Fernández-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Peña C, de Alarcón A, Ruiz J, Vilacosta I, Montejo M, Vallejo N, LópezMedrano F, Plata A, López J, Hidalgo C, Gálvez J, Sáez C, Lomas JM, **Falcone M**, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating *Enterococcus faecalis* infective endocarditis. *Clin Infect Dis* 2013; 56: 1261-8.
48. **Falcone M**, Russo A, Cassetta M, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? *J Infect Chemother* 2013; 19:732-9.
49. Vena A, **Falcone M**, Comandini E et al. Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant *Staphylococcus epidermidis*. *Diagn Microbiol Infect Dis.* 2013;76:99-102.
50. Guastalegname M, Russo A, **Falcone M**, Giuliano S, Venditti M. Candidemia subsequent to severe infection due to *Clostridium difficile*: is there a link? *Clin Infect Dis.* 2013; 57:772-4.
51. Ceccarelli G, **Falcone M**, Giordano A, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2013;57:2900-1.
52. **Falcone M**, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *Clin Infect Dis.* 2013;57:1568-76.
53. Russo A, **Falcone M**, Venditti M. Early identification of severe community-onset pneumonia in "frail elderly patient". *Intern Emerg Med.* 2013; 9:119-20.
54. **Falcone M**, Russo A, Mancone M, et al. Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study *Clin Microbiol Infect* 2014;20:758-63
55. Cangemi R, Calvieri C, Bucci T, Carnevale R, Casciaro M, Rossi E, Calabrese CM, Taliani G, Grieco S, **Falcone M**, et al. Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia? *Antioxid Redox Signal.* 2014; 20;20:2949-54.
56. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, **Falcone M**, et al. Guidelines for the management of the infection control measures to reduce hospitalization of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect* 2014; 20 Suppl 1:1-55.
57. **Falcone M**, Russo A, Venditti M. CAP and HCAP are different? An unresolved question. *Thorax.* 2014, 69:676-7.
58. Santagati M, Spanu T, Scillato M, Santangelo R, Cavallaro F, Arena V, Castiglione G, **Falcone M**, Venditti M, Stefani S. Three cases of rapidly fatal hemorrhagic pneumonia caused by group A *Streptococcus* serotype M1. *Emerg Infect Dis* 2014; 20:98-101.
59. Corrao S, Venditti M, Argano C, Russo A, **Falcone M**. Healthcare-associated pneumonia and multidrug-resistant bacteria: do we have a convincing answer? *Clin Infect Dis.* 2014;58:1196-7.
60. Guastalegname M, Grieco S, Giuliano S, **Falcone M**. A cluster of fulminant *Clostridium difficile* colitis in an intensive care unit in Italy. *Infection.* 2014; 42:585-9.
61. Pai MP, Russo A, Novelli A, Venditti M, **Falcone M**. Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. *Antimicrob Agents Chemother.* 2014;58:3162-3167.
62. **Falcone M**, Russo A, Venditti M, Novelli A, Pai MP. Reply to Di Paolo et al. *Clin Infect Dis.* 2014; 58: 1789-90
63. Rizzi M, Ravasio V, Carobbio A, Mattucci I, Crapis M, Stellini R, Pasticci MB, Chinello P, **Falcone M**, et al. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian study on endocarditis (SEI). *BMC Infect Dis.* 2014;14:230.
64. **Falcone M**, Concia E, Iori I, et al. Identification and management of invasive mycoses in internal medicine: a road-map for physicians. *Intern Emerg Med.* 2014; 9:501-11.
65. Russo A, Giuliano S, Vena A, Lucidi C, **Falcone M**, et al. Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role? *Diagn Microbiol Infect Dis.* 2014 May 21.
66. **Falcone M**, Vena A, Mezzatesta ML, et al. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae. *Ann Ig.* 2014;26: 293-304.
67. Giuliano S, Guastalegname M, Jenco M, Morelli A, **Falcone M**, Venditti M. Severe community onset healthcare-associated *Clostridium difficile* infection complicated by carbapenemase producing *Klebsiella pneumoniae* bloodstream infection. *BMC Infect Dis* 2014; 4:475.

68. Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, Taliani G, **Falcone M**, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. *J Am Coll Cardiol*. 2014;64:1917-25
69. **Falcone M**, Russo A, Cangemi R et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. *J Am Heart Assoc* 2015;4:e001595
70. Russo A, Campanile F, **Falcone M** et al. Linezolid-resistant staphylococcal bacteraemia: a multicentre case-case-control study in Italy. *Int J Antimicrob Agents* 2015;45:255-61
71. Russo A, **Falcone M**, Fantoni M, et al. Risk factors and clinical outcomes of candidaemia in patients treated for *Clostridium difficile* infection. *Clin Microbiol Infect* 2015; 21:493.e1-4.
72. **Falcone M**, Russo A, Giannella M et al. Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. *PLoS One* 2015; 10:e0119528.
73. **Falcone M**, Russo A, Venditti M. Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: New insights and evidence from the literature. *J Infect Chemother* 2015;21: 330-339.
74. Violi F, Calvieri C, **Falcone M**, Taliani G, Cangemi R; SIXTUS Study Group. Reply: platelets interplay between pneumonia and cardiovascular events: establishing a link? *J Am Coll Cardiol*. 2015;65:1489-90
75. Violi F, Calvieri C, **Falcone M**, Taliani G, Cangemi R; SIXTUS Study Group. Reply: myocardial infarction in patients with pneumonia. *J Am Coll Cardiol*. 2015;65:1491-2.
76. Violi F, Calvieri C, **Falcone M**, Taliani G, Cangemi R; SIXTUS Study Group. Reply: platelet activation and pneumonia: is soluble pselectin the right marker? *J Am Coll Cardiol*. 2015;65: 1493-4.
77. Merli M, Lucidi C, Di Gregorio V, **Falcone M**, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. *PLoS One*. 2015;10:e0127448.
78. Violi F, Carnevale R, Calvieri C, Nocella C, **Falcone M**, et al. Nox2 upregulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. *Thorax*. 2015; 70:961-6 79.
79. Cangemi R, Calvieri C, **Falcone M**, et al. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. *Am J Cardiol*. 2015;116:647-51.
80. **Falcone M**, Russo A, Pacini G, Merli M, Venditti M. Spontaneous bacterial peritonitis due to methicillin-resistant *Staphylococcus aureus* in a patient with cirrhosis: the potential role for daptomycin and review of the literature. *Infect Dis Rep*. 2015;7:6127.
81. Palma DM, Giuliano S, Cracchiolo AN, **Falcone M**, et al. Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases. *Infection*. 2016; 44:77-84 82.
82. **Falcone M**, Russo A, Iraci F, et al. Bloodstream infections secondary to *Clostridium difficile* infection: risk factors and outcomes. *Antimicrob Agents Chemother* 2015; 60:252-7.
83. **Falcone M**, Russo A, Merli M, Venditti M. Reply to: "The possible role of anti-methicillin-resistant *Staphylococcus aureus* antimicrobial agents in spontaneous bacterial peritonitis". *Infect Dis Rep* 2015; 7:6356.
84. **Falcone M**, Russo A, Farcomeni A, et al. Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination? *Intensive Care Med*. 2016; 42:301-2.
85. Durante-Mangoni E, Pafundi PC, Ravasio V, Barbaro F, Bassetti M, Chinello P, **Falcone M**, et al. Current features of infective endocarditis in persons on hemodialysis: a prevalence study with case control design from the prospective multicenter SEI cohort. *Infection* 2016; 44:467-74.
86. **Falcone M**, Tiseo G, Russo A et al. Hospitalization for pneumonia is associated with decreased 1-year survival in patients with type-2 diabetes: results from a prospective cohort study. *Medicine (Baltimore)* 2016; 95: e2531.
87. **Falcone M**, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Clin Microbiol Infect*. 2016; 22:444-50.
88. Russo A, **Falcone M**, Giuliano S, et al. Candidemia after heart valve replacement surgery: recurrence as prosthetic valve endocarditis is an expected over one-year complication. *Clin Microbiol Infect*. 2016; 22:466-7.
89. Merli M, Lucidi C, Di Gregorio V, Lattanzi B, Giannelli V, Giusto M, Farcomeni A, Ceccarelli G, **Falcone M**, et al. An empirical broad spectrum antibiotic therapy in healthcare-associated infections improves survival in cirrhotics: a randomized trial. *Hepatology* 2016; 63:1632-9.
90. Liu JL, Xu F, Zhou H, Wu XJ, Shi LX, Lu RQ, Farcomeni A, Venditti M, Zhao YL, Luo SY, Dong XJ, **Falcone M**. Expanded CURB65: a new score system predicts severity of community-acquired pneumonia with superior efficiency. *Sci Rep*. 2016;6: 22911.
91. Auriti C, Piersigilli F, Ronchetti M, Campi F, Amante P, **Falcone M**, Goffredo B. Shunt lock therapy with micafungin to treat shunt associated *Candida albicans* meningitis in an infant. *J Antimicrob Chemother* 2016; 71:2060-1.
92. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: report of a consensus conference. *Dig Liver Dis*. 2016;48:455-67.
93. **Falcone M**, Venditti M, Violi F. Role of aspirin in patients with septic shock: a complex and intriguing relationship. *Intensive Care Med*. 2016;42:1097.
94. **Falcone M**, Concia E, Giusti M, et al. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. *Intern Emerg Med*. 2016;11:637-48.
95. **Falcone M**, Venditti M, Sanguinetti M, Posteraro B. Management of candidemia in patients with *Clostridium difficile* infection. *Expert Rev Anti Infect Ther*. 2016;14:679-85
96. Cangemi R, Pignatelli P, Carnevale R, Bartimoccia S, Nocella C, **Falcone M**, et al. Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. *J Infect*. 2016;73:107-14.
97. Cangemi R, Della Valle P, Calvieri C, Taliani G, Ferroni P, **Falcone M**, et al. Low-grade endotoxemia and clotting activation in the early phase of pneumonia. *Respirology*. 2016; 21:1465-1471.
98. **Falcone M**, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. *J Antimicrob Chemother*. 2016; 71:2713-22.
99. Scudeller L, Bassetti M, Concia E, Corrao S, Cristini F, De Rosa FG, Del Bono V, Durante Mangoni E, **Falcone M**, et al. MEDical wards Invasive Candidiasis ALgorithms (MEDICAL): consensus proposal for management. *Eur J Intern Med* 2016 34:45-53.
100. Tascini C, **Falcone M**, Bassetti M, et al. Candidemia in patient with body temperature below 37°C and admitted to Internal Medicine Wards: assessment of risk factor. *Am J Med* 2016; 129:1330.e1-1330.e6.
101. **Falcone M**, Iraci F, Raponi G, et al. Nursing home residence is associated with spread of *Clostridium difficile* ribotype 027 in central Italy. *J Hosp Infect*. 2016 ;94:201-3.
102. Auriti C, **Falcone M**, et al. High-Dose Micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. *Antimicrob Agents Chemother*. 2016 ;60:7333-7339.

103. Loffredo L, Cangemi R, Perri L, Catasca E, Calvieri C, Carnevale R, Nocella C, Equitani F, Ferro D, Violi F; SIXTUS study group.; SIXTUS (thromboSIs-related eXTra-pulmonary oUtcomeS in pneumonia) study group., Battaglia S, Bertazzoni G, Biliotti E, Bucci T, Calabrese CM, Casciaro M, Celestini A, De Angelis M, De Marzio P, Esvan R, **Falcone M** et al. Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. *Eur J Intern Med.* 2016; 36:74-80.
104. Violi F, Cangemi R, **Falcone M**, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. *Clin Infect Dis* 2017; 64:1486-1493.
105. **Falcone M**, Tiseo G, Tascini C et al. Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: a multicenter study. *Eur J Intern Med.* 2017; 41:33-38.
106. **Falcone M**. Neglected tropical diseases in Europe: an emerging problem for health professionals. *Intern Emerg Med* 2017; 12:423-424.
107. Oliva A, Cipolla A, Vullo V, Venditti M, Mastroianni CM, **Falcone M**. Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant *Acinetobacter baumannii* causing ventilator-associated pneumonia. *New Microbiol.* 2017;40:205-207.
108. Trauer J, Muhi S, McBryde ES, Al Harbi SA, Arabi YM, Boyle AJ, Cartin-Ceba R, Chen W, Chen YT, **Falcone M**, et al. Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: an individual patient data meta-analysis using propensity matching. *Crit Care Med.* 2017;45:1871-1879.
109. Giuliano S, Guastalegname M, Russo A, **Falcone M**, et al. *Candida* endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. *Expert Rev Anti Infect Ther.* 2017;15:807-818.
110. **Falcone M**, Russo A, Gentiloni Silverj F et al. Predictors of mortality in nursing-home residents with pneumonia: a multicentre study. *Clin Microbiol Infect.* 2018;24:72-77
111. Ceccarelli G, Giuliano S, **Falcone M**, Venditti M. Follow-up blood cultures: A 2.0 diagnostic tool in patients with Gram-Negative bacteremia and septic thrombophlebitis. *Clin Infect Dis.* 2018; 66:1154-1155.
112. **Falcone M**, Viale P, Tiseo G, Pai M. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. *Expert Opin Drug Metab Toxicol.* 2018; 4:331-340.
113. **Falcone M**, Tiseo G, Durante-Mangoni E, et al. Risk factors and outcomes of endocarditis due to non-HACEK Gram-Negative bacilli: data from the Prospective Multicenter Italian Endocarditis Study cohort. *Antimicrob Agents Chemother.* 2018; ;62(4).
114. **Falcone M**, Tiseo G, Dentali F, et al. Predicting resistant etiology in hospitalized patients with blood cultures positive for Gram-negative bacilli. *Eur J Intern Med.* 2018;53:21-28.
115. Pieralli F, Vannucchi V, De Marzi G, Mancini A, Bacci F, Para O, Nozzoli C, **Falcone M**. Performance status and in-hospital mortality of elderly patients with community acquired pneumonia. *Intern Emerg Med.* 2018;13:501-507.
116. Menichetti F, **Falcone M**, Lopalco P, et al. The GISA call to action for the appropriate use of antimicrobials and the control of antimicrobial resistance in Italy. *Int J Antimicrob Agents.* 2018;52:127-134.
117. Russo A, **Falcone M**, Gutiérrez-Gutiérrez B, et al. Predictors of outcome in patients with severe sepsis or septic shock due to extended spectrum  $\beta$ -lactamase-producing Enterobacteriaceae. *Int J Antimicrob Agents* 2018;52:577-585.
118. Cangemi R, **Falcone M**, Taliani G, et al.; SIXTUS study group. Corticosteroid use and incident myocardial infarction in adults hospitalized for Community-Acquired Pneumonia. *Ann Am Thorac Soc.* 2019;16:91-98.
119. Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, **Falcone M**, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with *E. coli* or *Klebsiella pneumoniae* bloodstream infection and ceftriaxone resistance: a randomized clinical trial. *JAMA.* 2018 ;320:984-994.
120. **Falcone M**, Tiseo G, Iraci F, et al. Risk factors for recurrence in patients with *Clostridium difficile* infection due to 027 and non-027 ribotypes. *Clin Microbiol Infect.* 2019; 25:474-480.
121. **Falcone M**, Russo A, Shindo Y et al A hypothesis-generating study of the combination of aspirin plus macrolides in patients with severe community-acquired pneumonia. *Antimicrob Agents Chemother.* 2019;63(2). pii: e01556-18.
122. **Falcone M**, Paul M, Yahav D, et al. Antimicrobial consumption and impact of Antimicrobial Stewardship programmes in long-term care facilities. *Clin Microbiol Infect.* 2019; 25:562-569.
123. Tiseo G, Mazzone A, **Falcone M**. Identifying patients with acute bacterial skin and skin structure infection who need blood cultures. *Intern Emerg Med.* 2019; 14:203-206.
124. Pieralli F, Biondo B, Vannucchi V, **Falcone M**, et al. Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. *Eur J Intern Med.* 2019; 62:24-28
125. **Falcone M**, Tiseo G, Dentali F et al. Early alert from microbiology laboratory improves the outcome of elderly patients with *Enterococcus* spp bacteremia: results from a multicenter prospective study. *J Glob Antimicrob Resist.* 2019; 18:139-144.
126. **Falcone M**, Tiseo G, Venditti M, Menichetti F. Updates in the epidemiology and management of candidemia and *Clostridioides difficile* coinfection. *Expert Rev Anti Infect Ther.* 2019;17:375-382.
127. Kongnakorn T, Wagenlehner F, **Falcone M** et al Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. *Int J Antimicrob Agents.* 2019; 54:633-641.
128. Shepshelovich D, Tau N, Green H, Rozen-Zvi B, Issaschar A, **Falcone M** et al. Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey. *Transpl Infect Dis.* 2019; 21:e13134..
129. Cangemi R, Calvieri C, Taliani G, Pignatelli P, Morelli S, **Falcone M**, et al. Left atrium dilatation and left ventricular hypertrophy predispose to atrial fibrillation in patients with community-acquired pneumonia. *Am J Cardiol.* 2019; 124:723-728.
130. **Falcone M**, Tiseo G, Gutierrez-Gutierrez B et al. Impact of initial antifungal therapy on the outcome of patients with candidemia in septic shock admitted to medical wards: a propensity score adjusted analysis. *Open Forum Infect Dis* 2019; 6(7):ofz251.
131. Pérez-Nadales E, Gutiérrez-Gutiérrez B, Natera AM, Abdala E, Reina Magalhães M, Mularoni A, Monaco F, Camera Pierrotti L, Pinheiro Freire M, Iyer RN, Mehta Steinke S, Grazia Calvi E, Tumbarello M, **Falcone M**, et al. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: the impact of cytomegalovirus disease and lymphopenia. *Am J Transplant.* 2019 Dec 31.
132. Mancone M, Cavalcante R, Modolo R, **Falcone M** et al. Major infections after bypass surgery and stenting for multivessel coronary disease: an analysis of the randomized SYNTAX trial. *EuroIntervention.* 2020;15:1520-1526.
133. **Falcone M**, Tiseo G, Antonelli A, et al. Clinical features and outcomes of bloodstream infections caused by New Delhi Metallo- $\beta$ -lactamase-producing Enterobacterales during a regional outbreak. *Open Forum Infect Dis.* 2020 ;7(2):ofaa011
134. **Falcone M**, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing *Klebsiella pneumoniae*. *Crit Care.* 2020;24(1):29.
135. Tavoschi L, Forni S, Porretta A, Righi L, Pieralli F, Menichetti F, **Falcone M** et al. Prolonged outbreak of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019. *Euro Surveill.* 2020;25:2000085

136. **Falcone M**, Paul M, Tiseo G, et al. Considerations for the optimal management of antibiotic therapy in elderly patients. *J Glob Antimicrob Resist*. 2020;22:325-333.
137. Bassetti M, Vena A, Giacobbe DR, **Falcone M** et al. Ceftolozane/Tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study). *Open Forum Infect Dis*. 2020;7(5):ofaa139.
138. Russo A, Tiseo G, **Falcone M**, Menichetti F. Pulmonary aspergillosis: an evolving challenge for diagnosis and treatment. *Infect Dis Ther* 2020;9:511-524.
139. Coppelli A, Giannarelli R, Aragona M, Penno G, **Falcone M** et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. *Diabetes Care*. 2020; 43: 2345-2348.
140. Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP, Lin RTP, Chew KL, Yin M, Lee TH, Yilmaz M, Cakmak R, Alenazi TH, Arabi YM, **Falcone M**, et al. Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. *Clin Infect Dis*. 2020 Oct 27:ciaa1479.
141. Stebbing J, Sánchez Nieves G, **Falcone M**, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. *Sci Adv*. 2020;7(1):eabe4724.
142. **Falcone M**, Giordano C, Barnini S, et al. Extremely drug-resistant NDM-9-producing ST147 *Klebsiella pneumoniae* causing infections in Italy, May 2020. *Euro Surveill*. 2020;25:2001779.
143. Prendki V, Tau N, Avni T, **Falcone M**, et al. A systematic review assessing the under-representation of elderly adults in COVID-19 trials. *BMC Geriatr*. 2020; 20(1):538.
144. **Falcone M**, Tiseo G, Barbieri G, et al Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome Coronavirus 2 pneumonia: a prospective observational study. *Open Forum Infect Dis*. 2020;7(12):ofaa563.
145. Falcone M, Tiseo G, Menichetti F. Interpreting procalcitonin in patients undergoing hemodialysis: a reliable or a misleading marker? *Intern Emerg Med*. 2021;16:11-13.
146. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C, Ballerini PF, Sciascia R, Zammarchi L, Para O, Scotton PG, Inojosa WO, Ravagnani V, Salerno ND, Sainaghi PP, Brignone A, Codeluppi M, Teopompi E, Milesi M, Bertomoro P, Claudio N, Salio M, **Falcone M** et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. *JAMA Intern Med*. 2021; 181:24-31.
147. **Falcone M**, Russo A, Tiseo G, et al. Predictors of intensive care unit admission in patients with *Legionella pneumoniae*: role of the time to appropriate antibiotic therapy. *Infection*. 2021; 49: 321-325.
148. **Falcone M**, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. *Clin Infect Dis*. 2021; 72: 1871-1878.
149. Cassotta A, Goldstein JD, Durini G, Jarrossay D, Baggi Menozzi F, Venditti M, Russo A, **Falcone M**, et al. Broadly reactive human CD4+ T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire. *Eur J Immunol*. 2021; 51:648-661.
150. Mussini C, **Falcone M**, Nozza S, et al. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). *Clin Microbiol Infect*. 2021;27:389-395
151. **Falcone M**, Tiseo G, Giordano C, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. *J Antimicrob Chemother*. 2021; 76:1078-1084.
152. **Falcone M**, Menichetti F, Cattaneo D, et al. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. *J Antimicrob Chemother*. 2021; 76:1025-1031.
153. **Falcone M**, Tiseo G, Nicastrò M, et al. Cefiderocol as rescue therapy for *Acinetobacter baumannii* and other carbapenem-resistant Gram-negative infections in ICU patients. *Clin Infect Dis*. 2021; 72: 2021-2024.
154. Tinelli M, Tiseo G, **Falcone M**; ESCMID Study Group for Infections in the Elderly. Prevention of the spread of multidrug-resistant organisms in nursing homes. *Aging Clin Exp Res*. 2021; 33:679-687.
155. **Falcone M**, Tiseo G, Menichetti F. Community-acquired pneumonia owing to multidrug-resistant pathogens: a step toward an early identification. *Ann Am Thorac Soc*. 2021;18:211-213.
156. Giacobbe DR, Battagliani D, Enrile EM, Dentone C, Vena A, Robba C, Ball L, Bartoletti M, Coloretto I, Di Bella S, Di Biagio A, Brunetti I, Mikulska M, Caramante N, De Maria A, Magnasco L, Maraolo AE, Mirabella M, Montrucchio G, Patroniti N, Taramasso L, Tiseo G, Fornaro G, Fraganza F, Monastra L, Roman-Pognuz E, Paluzzano G, Fiorentino G, Corcione A, Bussini L, Pascale R, Corcione S, Tonetti T, Rinaldi M, **Falcone M** et al. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. *J Clin Med*. 2021;10:555.
157. Corradi F, Isirdi A, Malacarne P, Santori G, Barbieri G, Romei C, Bove T, Vetrugno L, **Falcone M**, et al. Low diaphragm muscle mass predicts adverse outcome in patients hospitalized for COVID-19 pneumonia: an exploratory pilot study. *Minerva Anestesiol* 2021;87:432-438.
158. Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, Luzzati R, Grossi PA, Corona A, Capone A, **Falcone M**, et al. Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study. *Clin Infect Dis*. 2021; 73:1664-1676.
159. Prete A, **Falcone M**, Bottici V, et al. Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. *Endocrine*. 2021;72:332-339.
160. **Falcone M**, Meier JJ, Marini MG, et al. Diabetes and acute bacterial skin and skin structure infections. *Diabetes Res Clin Pract* 2021;174:10873
161. Andreoni M, Bassetti M, Corrao S, De Rosa FG, Esposito V, **Falcone M**, et al. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. *Expert Rev Anti Infect Ther*. 2021; 16:1-10.
162. Mengozzi A, Georgiopoulos G, **Falcone M**, et al. The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. *Sci Rep*. 2021;11:6515.
163. Tiseo G, Arena F, Borrè S, Campanile F, **Falcone M**, et al. Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. *Expert Rev Anti Infect Ther*. 2021; 14:1-11
164. Cangemi R, Carnevale R, Cammisotto V, Nocella C, Bartimoccia S, Taliani G, **Falcone M**, et al. Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia. *Br J Clin Pharmacol*. 2021; 88:155-165
165. **Falcone M**, De Angelis B, Pea F, et al. Challenges in the management of chronic wound infections. *J Glob Antimicrob Resist* 2021;26:140-147.
166. Nieri D, Neri T, Barbieri G, Moneta S, Morelli G, Mingardi D, Spinelli S, Ghiadoni L, **Falcone M**, et al. C-C motive chemokine ligand and thrombo inflammation in COVID-19-associated pneumonia: a retrospective study. *Thromb Res*. 2021; 204:88-94.



167. Tiseo G, **Falcone M**, Leonildi A et al. Meropenem-Vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 *Klebsiella pneumoniae*-producing KPC-31, a D179Y Variant of KPC-3. *Open Forum Infect Dis*. 2021;8(6):ofab141
168. **Falcone M**, Tiseo G, Galfo V, et al. Bloodstream infections in patients with rectal colonization by *Klebsiella pneumoniae* producing different type of carbapenemases: a prospective, cohort study (CHIMERA study). *Clin Microbiol Infect*. 2021:S1198-743X(21)00362-1.
169. Luci G, Mattioli F, **Falcone M**, Di Paolo A. Pharmacokinetics of non- $\beta$ -lactam  $\beta$ -lactamase inhibitors. *Antibiotics (Basel)*. 2021;10:769.
170. **Falcone M**. Education: a overview from the author of 'cefiderocol as rescue therapy for *Acinetobacter baumannii* and other carbapenem-resistant Gram-negative infections in intensive care unit patients'. *JAC Antimicrob Resist*. 2021;3(Suppl 1):i25.
171. Reigadas E, van Prehn J, **Falcone M**, et al. How to: prophylactic interventions for prevention of *Clostridioides difficile* infection. *Clin Microbiol Infect*. 2021:S1198-743X(21)00368-2
172. Gill CM, Aktap E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, **Falcone M**, et al. The ERACE-PA global surveillance program: ceftolozane/tazobactam and ceftazidime/avibactam *in vitro* activity against a global collection of carbapenem resistant *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis*. 2021; 40:2533-2541.
173. Gill CM, Aktap E, Alfouzan W, Bourassa L, Brink A, Burnham CA, Canton R, Carmeli Y, **Falcone M**, et al. Elevated MICs of susceptible anti-pseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant *Pseudomonas aeruginosa*: implications for dose optimization. *Antimicrob Agents Chemother*. 2021; 65(11):e0120421
174. **Falcone M**, Tiseo G, Valoriani B et al. Efficacy of bamlanivimab/etesevimab and casirivimab/indevimab in preventing progression to severe COVID-19 and role of variants of concern. *Infect Dis Ther* 2021; 10:2479-2488.
175. Stamatiopoulos G, Georgiopoulos G, Baker KF, Tiseo G, Delialis D, Lazaridis C, Barbieri G, Masi S, Vlachogiannis NI, Sopova K, Mengozzi A, Ghiadoni L, van der Loeff IS, Hanrath AT, Ajdini B, Vlachopoulos C, Dimopoulos MA, Duncan CJA, **Falcone M**, Stellos K; Pisa COVID-19 Research Group; Newcastle COVID-19 Research Group. Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19. *Sci Rep*. 2021;11:20239.
176. Cangemi R, Calvieri C, **Falcone M**, et al. Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicentre observational study. *Thromb Haemost*. 2021 Nov 10.
177. Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio GV, Luchi S, Blanc P, Puoti M, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi LR, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini L, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace L, Lanza M, Focosi D, Mazzoni A, Pistello M, **Falcone M**; TSUNAMI Study group. Effect of hightiter convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. *JAMA Netw Open*. 2021;4:e2136246.
178. Bertini P, Guarracino F, **Falcone M**, et al. ECMO in COVID-19 patients: a systematic review and meta-analysis. *J Cardiothorac Vasc Anesth*. 2021 Nov 12:S1053-0770(21)00971-X.
179. Scalise A, **Falcone M**, Avruscio G, et al. What COVID-19 taught us: new opportunities and pathways from telemedicine and novel antiseptics in wound healing. *Int Wound J*. 2022 19:987-995.
180. Fabiani S, Caroselli C, Menchini M, Gabbriellini G, **Falcone M**, Bruschi F. Ocular toxoplasmosis, an overview focusing on clinical aspects. *Acta Trop*. 2022;225:106180.
181. Cattaneo D, **Falcone M**, Gervasoni C, Marriott DJ. Therapeutic drug monitoring of antibiotics in the elderly: a narrative review. *Ther Drug Monit*. 2022 Feb 1;44:75-85.
182. Tiseo G, Yahav D, Paul M, Tinelli M, Gavazzi G, Mussini C, Prendki V, **Falcone M**. What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. *Eur J Clin Microbiol Infect Dis*. 2022;41:281-288.
183. Menichetti F, **Falcone M**, Tiseo G. Management of COVID patients with convalescent plasma: do we have the final word? *Eur J Intern Med*. 2022;95:13-16.
184. Ceccato A, Russo A, Barbata E, Oscanoa P, Tiseo G, Gabarrus A, Di Giannatale P, Nogas S, Cilloniz C, Menichetti F, Ferrer M, Niederman M, **Falcone M**, Torres A. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. *Crit Care*. 2021;25(1):432.
185. **Falcone M**, Tiseo G, Arcari G, et al. Spread of hypervirulent multidrug-resistant ST147 *Klebsiella pneumoniae* in patients with severe COVID-19: an observational study from Italy, 2020-21. *J Antimicrob Chemother*. 2022 Jan 18:dkab495.
186. Gill CM, Aktap E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, **Falcone M**, et al. Multicenter, prospective validation of a phenotypic algorithm to guide carbapenemase testing in carbapenem-resistant *Pseudomonas aeruginosa* using the ERACE-PA Global Surveillance Program. *Open Forum Infect Dis*. 2021;9(2):ofab617.
187. **Falcone M**, Suardi LR, Tiseo G et al. Early Use of Remdesivir and risk of disease progression in hospitalized Patients with mild to moderate COVID-19. *Clin Ther*. 2022:S0149-2918(22)00012-1.
188. **Falcone M**, Tiseo G. Cefiderocol for the treatment of metallo-beta-lactamases producing Gram negative bacilli: lights and shadows from the literature. *Clin Infect Dis*. 2022 Feb 5:ciac082.
189. Tiseo G, Fais R, Forniti A, Melandro F, Tavanti A, Ghelardi E, De Simone P, **Falcone M**, Lupetti A. Fatal fungemia by biofilm producing *Trichosporon asahii* in a liver transplant candidate. *Infez Med*. 2021;29(3):464-468.
190. Yelin D, Margalit I, Nehme M, Bordas-Martinez J, Pistelli F, Yahav D, Guessous I, Durà-Miralles X, Carrozzi L, Shapira-Lichter I, Vetter P, Peleato-Catalan D, Tiseo G, Wirtheim E, Kaiser L, Gudiol C, **Falcone M**, Leibovici L, on behalf of the LongCOV Research Group. Patterns of long COVID symptoms: a multi-center cross sectional study. *J Clin Med*. 2022;11:898.
191. Riccardi N, **Falcone M**, Yahav D. Vaccination for SARS-CoV-2 in hematological patients. *Acta Haematol*. 2022;145:257-266.
192. Violi F, Pignatelli P, Vestri A, Spagnoli A, Cipollone F, Ceccarelli G, Oliva A, Amitrano M, Pirro M, Taliani G, Cangemi R, Lichtner M, Pugliese F, **Falcone M** et al. The ADA (age-d-dimer-albumin) score to predict thrombosis in SARS-CoV-2. *Thromb Haemost*. 2022 Mar 4.
193. Moscato G, Mazzetti P, Lucenteforte E, Rosellini A, Cara A, Quaranta P, Mainardi V, Villa P, Focosi D, Lanza M, Bianco I, Mazzoni A, **Falcone M**, et al. Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody. *J Clin Virol Plus*. 2021;1:100016.
194. Tumbarello M, Raffaelli F, Cascio A, **Falcone M** et al. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing *Klebsiella pneumoniae*: a multicentre study. *JAC Antimicrob Resist*. 2022;4(1):dlac022.
195. Prendki V, Tiseo G, **Falcone M**; ESCMID Study Group for Infections in the Elderly (ESGIE). Caring for older adults during the COVID-19 pandemic. *Clin Microbiol Infect*. 2022;28:785-791.
196. **Falcone M**, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2022;66:e0214221.

197. Bezinover D, Biancofiore G, **Falcone M**, et al. Multidrug-resistant infections in solid organ transplant recipients: a focus on risk factors, prevention and treatment strategies. *Minerva Anesthesiol.* 2022 Mar 22. doi: 10.23736/S0375-9393.22.16124-9.
198. Cacopardo B, Cattaneo D, Cortese F, Di Luca M, **Falcone M**, et al. Role of dalbavancin as combination therapy: evidence from the +literature and clinical scenarios. *Expert Rev Anti Infect Ther.* 2022; 8:1-8.
199. Margalit I, Prendki V, Tishler O, Falcone M, et al. Effectiveness and safety of colistin among older adults: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2022 May 5:dkac145.
200. Franconi I, Leonildi A, Erra G, Fais R, **Falcone M** et al. A. Comparison of different microbiological procedures for the diagnosis of *Pneumocystis jirovecii* pneumonia on bronchoalveolar-lavage fluid. *BMC Microbiol.* 2022;22(1):143.
201. Bertini P, Paternoster G, Landoni G, **Falcone M**, et al. Beneficial effects of levosimendan to wean patients from VA-ECMO: a systematic review and meta-analysis. *Minerva Cardiol Angiol.* 2022 Jun 10.
202. Forniti A, Riccardi N, Sponga P, Buono C, Iapoco R, Suardi LR, Tiseo G, **Falcone M**, Menichetti F. Recrudescence of *Plasmodium falciparum* malaria 5 years after treatment in an HIV migrant: a case report with a peculiar presentation. *Infez Med.* 2022;30:304-308.
203. Tiseo G, Brigante G, Giacobbe DR, Maraolo AE, Gona F, **Falcone M**, et al. Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). *Int J Antimicrob Agents.* 2022;60:106611
204. **Falcone M**, Suardi LR, Tiseo G, et al. Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study). *JAC Antimicrob Resist.* 2022;4(3):dlac064.
205. Balice G, Passino C, Bongiorno MG, Segreti L, Russo A, Lastella M, Luci G, **Falcone M**, Di Paolo A. Daptomycin population pharmacokinetics in patients affected by severe gram-positive infections: an update. *Antibiotics (Basel).* 2022;11(7):914.
206. Berchiolli R, Bertagna G, Erba PA, Caroselli C, Fabiani S, Suardi LR, **Falcone M**, Ferrari M, Troisi N. A rare case of mycobacterial pseudoaneurysm of the superficial femoral artery. *Eur Rev Med Pharmacol Sci.* 2022;26:5250-5254.
207. Occhineri S, Matucci T, Rindi L, Tiseo G, **Falcone M**, Riccardi N, Besozzi G. Pretomanid for tuberculosis treatment: an update for clinical purposes. *Curr Res Pharmacol Drug Discov.* 2022;3:100128.
208. Tiseo G, Suardi LR, Giusti L, ...and **Falcone M**. Predictors and outcomes of respiratory bacterial coinfections in patients with COVID19 admitted to hospital: an observational prospective study. *Respirology.* 2022;27(11):987-990.
209. Mingione M, Ciccozzi M, **Falcone M**, Maruotti A. Short-term forecasts of Monkeypox cases in multiple countries: keep calm and don't panic. *J Med Virol.* 2022 Sep 19.
210. Riccardi N, Antonello RM, Giacomelli A, Saderi L, Canetti D, Pallotto C, Mazzaferri F, Degli Antoni AM, Cardellino C, Motta I, Calcagno A, **Falcone M**, et al. The challenge of infectious diseases consultations in the emergency department: an Italian nationwide survey. *New Microbiol.* 2022;45(4).
211. Daitch V, Yelin D, Awwad M, Guaraldi G, Milić J, Mussini C, **Falcone M**, et al. Characteristics of long COVID among older adults: a cross-sectional study. *Int J Infect Dis.* 2022:S1201-9712(22)00535-5.
212. Tiseo G, Margalit I, Ripa M, ...and, **Falcone M**; ESCMID Study Group for Infections in the Elderly (ESGIE). Predictors of survival in elderly patients with coronavirus disease 2019 admitted to the hospital: derivation and validation of the FLAMINCOV score. *Clin Microbiol Infect.* 2022:S1198-743X(22)00511-0
213. Giacobbe DR, Vena A, **Falcone M**, Menichetti F, Bassetti M. Fidaxomicin for the Treatment of *Clostridioides difficile* infection in adult patients: an update on results from randomized controlled trials. *Antibiotics (Basel).* 2022;11(10):1365.
214. Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, Galliez RM, Garlin AB, Nozza S, Mitja O, Radix AE, Blanco JL, Crabtree-Ramirez B, Thompson M, Wiese L, Schulbin H, Levcovich A, **Falcone M**, et al. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series. *Lancet.* 2022:S0140-6736(22)02187-0.
215. Tiseo G, Barbieri C, Galfo V, ...and **Falcone M**. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real world cohort of outpatients with COVID-19 at high risk of progression: the PISA Outpatient Clinic experience. *Infect Dis Ther.* 2023;12:257-271.
216. Loffredo L, Pignatelli P, Pirro M, Ceccarelli G, Oliva A, Maggio E, Cancelli F, D'Ardes D, Amitrano M, Zicari AM, Cinicola BL, Taliani G, Cangemi R, Lichtner M, **Falcone M**, et al Association between PaO<sub>2</sub>/FiO<sub>2</sub> ratio and thrombotic events in COVID-19 patients. *Intern Emerg Med.* 2023;18(3):889-895.
217. **Falcone M**, Tiseo G. Skin and soft tissue infections in the elderly. *Curr Opin Infect Dis.* 2023;36(2):102-108.
218. Galfo V, Riccardi N, Leonildi A, **Falcone M**, Barmini S. Pharyngeal and cutaneous diphtheria: a tail of a refugee. *Infection.* 2023; 51:1599-1600
219. **Falcone M**, Tiseo G, Carbonara S, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram negative bacilli: results from a nationwide study in Italy (ALARICO Network). *Clin Infect Dis.* 2023; 76:2059-2069
220. De Vito A, Fiore V, Colpani A, Zauli B, Fanelli C, Tiseo G, Occhineri S, Babudieri S, **Falcone M**, Madeddu G. The current and future off-label uses of dalbavancin: a narrative review. *Eur Rev Med Pharmacol Sci.* 2023 ;27:1222-1238.
221. Matucci T, Riccardi N, Occhineri S, Pontarelli A, Tiseo G, **Falcone M**, et al. Treatment of latent tuberculosis infection in incarcerated people: a systematic review. *Clin Microbiol Infect.* 2023; 29:714-721.
222. Tiseo G, Galfo V, Occhineri S, Forniti A, Caroselli C, **Falcone M**, Menichetti F. Risk factors and outcomes of fungal superinfections in patients with severe COVID-19: an observational study from Pisa academic hospital. *Infez Med.* 2023;31:55-61.
223. **Falcone M**, Bauer M, Ferrer R, et al. Biomarkers for risk stratification and antibiotic stewardship in elderly patients. *Aging Clin Exp Res.* 2023 Mar 30:1-11.
224. Pérez-Nadales E, Fernández-Ruiz M, Natera AM, Gutiérrez-Gutiérrez B, Mularoni A, Russell G, Pierrotti LC, Freire MP, **Falcone M**, et al Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase producing *Klebsiella pneumoniae*. *Am J Transplant.* 2023:S1600-6135(23)00354-4.
225. Gentile I, Buonomo AR, Corcione S, Paradiso L, Giacobbe DR, Bavaro DF, Tiseo G, Sordella F, Bartoletti M, Palmiero G, Voza A, Vena A, Canta F, Moriello NS, Congera P, Karruli A, Tascini C, Viale P, Bono VD, **Falcone M**, et al. CEFTObiprole Clinical Use in Real-life - a multi-centre experience in Italy. *Int J Antimicrob Agents.* 2023 Apr 13:106817.
226. Margalit I, Tiseo G, Ripa M, Borghi V, Green H, Prendki V, Riccardi N, Perego GB, Grembiale A, Galli L, Tinelli M, Castagna A, Mussini C, **Falcone M**, Yahav D. Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study. *J Antimicrob Chemother.* 2023;78:1505-1509.
227. Graziani M, Barbieri C, Maraziti G, **Falcone M**, et al.. The role of prone positioning in patients with SARS-CoV-2-related respiratory failure in non-intensive care unit. *Ther Adv Respir Dis.* 2023;17:17534666231164536.

228. Oliva A, Carbonara S, Cianci V, Crapis M, Di Domenico EG, **Falcone M**, et al. Direct or early discharge of acute bacterial skin and skin structure infection patients from the Emergency Department/Unit: place in therapy of dalbavancin. *Expert Rev Anti Infect Ther*. 2023;21(7):703-721.
229. Raccagni AR, Leoni D, Ciccullo A, Verdenelli S, Cattelan AM, Di Giambenedetto S, **Falcone M**, et al. Rapid improvement of severe Mpox lesions with oral tecovirimat. *J Med Virol*. 2023;95(6):e28825.
230. Tiseo G, Giordano C, Leonildi A, Riccardi N, Galfò V, Limongi F, Nicastro M, Barnini S, **Falcone M**. Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant *Acinetobacter baumannii* in a critically ill burn patient: clinical challenges and molecular characterization. *JAC Antimicrob Resist*. 2023;5(3):dlad078.
231. Cortegiani A, Antonelli M, **Falcone M**, et al. Rationale and clinical application of antimicrobial stewardship principles in the intensive care unit: a multidisciplinary statement. *J Anesth Analg Crit Care*. 2023;3:11.
232. Cortegiani A, Ingoglia G, Ippolito M, Girardis M, **Falcone M**, et al. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement. *J Anesth Analg Crit Care*. 2022;2:34.
233. Tiseo G, Suardi LR, Leonildi A, Giordano C, Barnini S, **Falcone M**. Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo- $\beta$ -lactamase-producing *Klebsiella pneumoniae* infections. *J Antimicrob Chemother*. 2023 Jul 1:dkad206.
234. Coccolini F, Sartelli M, Sawyer R, Rasa K, Viaggi B, Abu-Zidan F, Soreide K, Hardcastle T, Gupta D, Bendinelli C, Ceresoli M, Shelat VG, Broek RT, Baiocchi GL, Moore EE, Sall I, Podda M, Bonavina L, Kryvoruchko IA, Stahel P, Inaba K, Montravers P, Sakakushev B, Sganga G, Ballestracci P, Malbrain MLNG, Vincent JL, Pikoulis M, Beka SG, Doklestic K, Chiarugi M, **Falcone M**, et al. Source control in emergency general surgery: WSES, GAIS, SIS-E, SIS-A guidelines. *World J Emerg Surg*. 2023 Jul 21;18(1):41.
235. Monami M, Scatena A, Miranda C, Monge L, De Cassai A, Volpe A, Tramonta R, Medea G, Bordieri C, **Falcone M**, et al. Development of the Italian clinical practice guidelines for the treatment of diabetic foot syndrome: design and methodological aspects. *Acta Diabetol*. 2023;60:1449-1469.
236. Giannella M, Verardi S, Karas A, Abdel Hadi H, Dupont H, Soriano A, Santerre Henriksen A, Cooper A, **Falcone M**; ARES Study Group. Carbapenem-resistant *Acinetobacter* spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic. *Open Forum Infect Dis*. 2023 Jul 4;10(7):ofad329.
237. Caroselli C, Suardi LR, Besola L, Fiocco A, Colli A, Falcone M. Native-valve *Aspergillus* endocarditis: case report and literature review. *Antibiotics (Basel)*. 2023 ; 12:1190.
238. Riccardi N, Occhineri S, Matucci T, Marchetti G, Rindi L, Tiseo G, Cirillo DM, **Falcone M**. Bedaquiline-based all-oral regimen for macrolide-resistant *Mycobacterium abscessus* pulmonary disease. *Int J Tuberc Lung Dis*. 2023;27:712-713.
239. Maraziti G, Marchini L, Barbieri G, **Falcone M**, et al. Arterial lactate as a risk factor for death in respiratory failure related to coronavirus disease 2019: an observational study. *Ther Adv Respir Dis*. 2023 Jan-Dec;17:17534666231186730.
240. Tiseo G, Galfò V, **Falcone M**. What is the clinical significance of 'heteroresistance' in nonfermenting Gram-negative strains? *Curr Opin Infect Dis*. 2023;36:555-563.
241. Franconi I, Rizzato C, Tavanti A, **Falcone M**, Lupetti A. Paradigm shift: *Candida parapsilosis* sensu stricto as the most prevalent *Candida* species isolated from bloodstream infections with increasing azole-non-susceptibility rates: trends from 2015-2022 survey. *J Fungi (Basel)*. 2023;9:1012.

PISA 28-11-2023

